Open an account

Panbela Therapeutics

PBLA · OTC

$0.001+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.001

About PBLA

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 7 full-time employees. The company went IPO on 2014-07-29. The firm is developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company’s lead candidates are ivospemin (SBP-101), for which it has licensed the worldwide rights from the University of Florida Research Foundation, Inc., Flynpovi, a combination of eflornithine (CPP-1X) and sulindac and eflornithine (CPP-1X), alone in tablet or sachet form. The company has licensed rights from the Arizona Board of Regents of the University of Arizona to commercialize Flynpovi. Additionally, eflornithine is being evaluated with high dose testosterone and enzalutamide in metastatic castration-resistant prostate cancer in a phase II trial. The firm is engaged in over two sponsored research agreements to evaluate the polyamines individually and combined for various diseases.

Employees
7
Headquarters
Waconia, Minnesota
Listed
Jul 29, 2014
Sector
Health Care
Industry
Biotechnology
Website
panbela.com

PBLA key statistics

Market cap
4.85K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.27K
Volume
6.34K
Open price
$0.001
High today
$0.001
Low today
$0.001
52 Week high
$0.0551
52 Week low
$0.00

Panbela Therapeutics (PBLA) at a glance

Panbela Therapeutics (PBLA) last traded at $0.001, with a market cap of 4.85K and a price-to-earnings ratio of 0.00.

Volume so far is 6.34K shares, above the average of 2.27K shares a day.

Over the past year Panbela Therapeutics has ranged from $0.00 to $0.0551, and now sits 2% of the way up that range.

Panbela Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q3 FY24 it reported -$1.48 per share against an estimate of -$1.23.

PBLA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 15.0% on average.

  1. Q4 FY22: reported -$3,408.00 per share against an estimate of -$2,267.46
  2. Q1 FY23: reported -$390.00 per share against an estimate of -$328.44
  3. Q2 FY23: reported -$159.08 per share against an estimate of -$95.98
  4. Q3 FY23: reported -$53.80 per share against an estimate of -$42.02
  5. Q4 FY23: reported -$65.90 per share against an estimate of -$24.83
  6. Q1 FY24: reported -$2.28 per share against an estimate of -$1.65
  7. Q2 FY24: reported -$1.47 per share against an estimate of -$1.73
  8. Q3 FY24: reported -$1.48 per share against an estimate of -$1.23

Similar companies

Companies in the same industry as Panbela Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.